<DOC>
	<DOCNO>NCT00558220</DOCNO>
	<brief_summary>The purpose study show addition Rituximab intensive induction ( MegaCHOP/ESHAP ) high-dose consolidation ( BEAM ) improve progression-free overall survival patient young 65 year aggressive B-cell lymphoma aaIPI 2 3 .</brief_summary>
	<brief_title>R-MegaCHOP-ESHAP-BEAM Patients With High-Risk Aggressive B-Cell Lymphomas</brief_title>
	<detailed_description>Previous study Czech Lymphoma Study Group ( 4_2002 ) show intensive induction ( MegaCHOP - Cyclophosphamide 3 g/m2 , Vincristine 2 mg , Adriamycin 75 mg/m2 , Prednisone 300 mg/m2 every three week G-CSF three cycle , follow ESHAP - Etoposide 240 mg/m2 , Cisplatin 100 mg/m2 , Solumedrol 2000 mg cytarabine 2000 mg/m2 three cycle every three week G-CSF ) follow intensive consolidation ( BEAM ) stem cell support improve progression-free survival adult patient ( 18-65 year old ) aggressive B-cell lymphoma ( namely , diffuse large B-cell lymphoma , primary mediastinal B-cell lymphoma follicular lymphoma grade II ) aaIPI 2 namely , aaIPI 3 . This study aim find addition four six dos Rituximab 375 mg/m2 first day every cycle intensive induction improve prognosis patient . Inclusion criterion trial : - newly diagnose aggressive B-cell lymphoma , namely diffuse large B-cell lymphoma , primary mediastinal B-cell lymphoma follicular lymphoma grade III - age 18-65 year - age adjust IPI ( International Prognostic Index ) score 2 3 - ECOG performance status 0-3 - sign informed consent Exclusion criterion : - relapse lymphoma - previous treatment ( one cycle standard pretreatment - COP , CHOP steroids permit later become mandatory decrease disease burden and/or improve performance status patient ) - Burkitt lymphoma - posttransplant lymphoproliferation - CNS involvement - malignant tumor previous history , except basalioma , skin squamocellular carcinoma cervical carcinoma situ - serious comorbidity Primary endpoints progression-free survival Secondary endpoint : - rate complete remission overall response rate - overall survival - toxicity protocol , measure grade III-IV toxicity and/or inability finish protocol plan Planned number accrue patient 100 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<criteria>Aggressive Bcell lymphoma , namely diffuse large Bcell lymphoma , primary mediastinal Bcell lymphoma , follicular lymphoma grade III Age 1865 year Ageadjusted IPI score 23 ECOG performance status 03 Signed inform consent Burkitt lymphoma Posttransplant lymphoproliferation Previous treatment ( one cycle standard pretreatment COP , CHOP steroid permit latter mandatory decrease tumor burden and/or improve performance status ) Other tumor previous history exception basalioma , squamous cell carcinoma skin cervical carcinoma situ Pregnancy/lactation CNS involvement Other serious comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>Lymphoma , B-cell</keyword>
	<keyword>Immunotherapy , passive</keyword>
	<keyword>Remission induction</keyword>
	<keyword>Autologous transplantation</keyword>
</DOC>